Clinical Trial

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a study of the safety and effectiveness of Trametinib treatment in patients who have received successful endoscopic submucosal resection of a Stage I gastric cancer.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04454476
Lead Sponsor Vanderbilt-Ingram Cancer Center
Conditions Gastric Cancer, Metaplasia, Stage I Gastric Cancer, Initial-onset Gastric Cancer
Enrollment 15 participants
Start Date 2022-11-09
Primary Completion 2024-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-31